Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and ...

Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide ...

Shares of Hims & Hers Health, Inc. (HIMS) marked their best session in nearly three months on Tuesday, surging over 23% after ...

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

Jonathan Rockoff is the Health Business editor at The Wall Street Journal, managing a team that reports on pharmaceutical and biotechnology companies, health insurers and hospitals. During the ...

If approved, the less burdensome version of Leqembi could be used to treat patients at home or in medical facilities, help Eisai and Biogen differentiate Leqembi from Eli Lilly's recently approved ...

Eli Lilly, the manufacturer of Zepbound, made Zepbound available on its online pharmacy, LillyDirect, in August 2024. The medication is available as a single-dose vial or an auto-injector pen.

The last couple of quarters have been very favorable for Eli Lilly and Company (NYSE:LLY) and its position in the obesity and adjacent markets. The main competitor Novo Nordisk A/S (NVO ...

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results tomorrow before market hours. Here’s what to look for. Eli Lilly met analysts’ revenue expectations last quarter ...

Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed oligonucleotide therapies from Creyon Bio. Oligonucleotides work as ...